Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Title Grant Type Focus Area Country Application Due Date Education for Improving Appropriate Diagnosis and Treatment for Venous ThromboembolismRelease Date:Education Internal Medicine Japan Education and Support for Patients with Locally-Advanced or Metastatic Bladder CancerRelease Date:Partner: Merck KGaA, Darmstadt, Germany and EMD SeronoEducation Oncology USA Pre-clinical & Translational Research in Multiple MyelomaRelease Date:Research Oncology Canada, USA Management of Patients with BRAF-mutant metastatic colorectal cancerRelease Date:Education Oncology Canada, USA Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare DiseaseRelease Date:Quality Improvement Rare Disease All Promotion of Smoking Cessation Treatment in General PracticeRelease Date:Education Internal Medicine Japan 2021 Growth Hormone Research (All countries except for the United States)Release Date:Research Rare Disease All Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis PainEducation Internal Medicine All NSCLC Therapy Management for Optimal OutcomesRelease Date:Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom Clinical Research Capability DevelopmentRelease Date:Education Internal Medicine China Educational Program to Increase Awareness and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease China Advances in Moderate-to-Severe Atopic Dermatitis for Dermatologists and AllergistsRelease Date:Education Inflammation & Immunology USA